The U.S. Food and Drug Administration’s panel of outside experts did not lend its support to Cytokinetics Inc.’s heart drug, citing insufficient data on safety and efficacy.
Tag Archive for: Cardiovascular and Renal Drug Advisory Committee
On Nov.16, the FDA’s Cardiovascular and Renal Drug Advisory Committee will meet to assess the data supporting Ardelyx’s New Drug Application for tenapanor in chronic kidney disease.